Home > PORTAL > about Us > Presentation >
Learn how SPIN got started
SPIN – Skin Inflammation & Psoriasis International Network was initiated in 2004 as PIN – Psoriasis International Network by the FRT - Fondation René Touraine, a non-profit and a non-governmental organisation dedicated to support therapeutic progress in dermatology by fostering international collaborations.
After several European meetings on psoriasis held in Italy every 2 or 3 years, the FRT and Prof. Louis Dubertret organised the European Congress on Psoriasis - PSO 2004 in Paris, which acquired a great international dimension, with over 600 participants from 40 different countries. Following the PSO 2004 Congress, many participants showed great interest in developing networking activities in the field of psoriasis.
The founding meeting of the former PIN was held in Paris (Nov 18, 2005) between 20 countries willing to develop national psoriasis groups and willing to connect these groups into an international network. 11 countries were able to send a representative and 9 additional countries expressed a strong interest but were unable to come. The President of EUROPSO, the European federation of psoriasis associations, participated as well in the founding meeting.
This founding meeting formalised the international collaborations in the field of psoriasis started with the PSO 2004 Congress, creating thus the Psoriasis International Network. To develop this international network, it was proposed to:
• set up a website: www.psoriasis-international.org (now www.spindermatology.org!)
• organise every 3 years an International Congress on Psoriasis in Paris
• publish regular newsletters and "Focus On”
In 2011, a Scientific Committee was created to steer the scientific development of the network by proposing international collaborative projects, contributing to continuing medical training in psoriasis and supporting the development of national and regional psoriasis networks.
The network has grown ever since, gathering around 4700 healthcare professionals involved in the management of psoriasis from some 100 countries, 330 dermatology centres as well as 43 patient organisations. Since 2004, PIN has successfully:
• organised 5 international congresses on psoriasis and educational symposia during other dermatology meetings
• built a worldwide directory listing psoriasis medical resources for patients
• provided organisational support to the development of dedicated outpatient consultations at the local level
• fostered the development of national and regional networks on psoriasis
• carried out international studies on the current practice of the use of methotrexate and phototherapy in the treatment of psoriasis
• initiated a worldwide survey on the use of therapeutic patient education in psoriasis with the aim of developing a toolbox
• collaborated with the EADV Psoriasis Task Force since 2005.
In 2016, it was decided by the FRT Board of Directors to broaden the scope of the PIN to include other major chronic inflammatory skin diseases. This would allow to benefit from the benchmark of PIN’s actions and achievements in psoriasis and put it to the service of other diseases. With this change, we hope to transfer the know-how acquired on psoriasis (highest standard in issues such as quality of life, high burden and co-morbidities) and build on the collaborations made possible via the PIN network and expand them to other major chronic skin inflammatory diseases.
Following this decision, the former PIN Scientific Committee has decided to change the name of the network to SPIN – Skin Inflammation & Psoriasis International Network. On an operational level, the Committee decided to broaden the network’s scope progressively, one chronic inflammatory skin disease at a time. Starting in 2017, the new SPIN will cover psoriasis and expand its activities to atopic dermatitis.
SPIN Presentation
Recent news
- 2019/10/29 Focus on...
- 2019/08/12 Focus on...
Latin American Clinical Practice Guidelines on the Systemic Treatment of Psoriasis
- 2019/06/03 Focus on...
- 2019/05/21 Focus on...
- 2019/04/18 Focus on...
News from the web office
- 2016/10/29
- 2016/05/26
- 2016/02/20
Events
- 2019/04/18 Focus on...
- 2018/02/21
News from medical groups
- 2018/04/18
- 2017/06/21
News from patients associations
- 2017/02/08
- 2016/05/26
Recent publications on Psoriasis and Atopic Dermatitis
on Psoriasis
Melissa officinalis ssp. altissima extracts: A therapeutic approach targeting psoriasis in mice.
J Ethnopharmacol.
2020 Jan 10, 246:112208.
Melissa officinalis L., commonly known as lemon balm, is one of the most well known edible and medicinal plants of the Lamiaceae family. It is quoted in almost all known medical treatises, from Antiquity up to modern era, such as Corpus Hippocraticum, Dioscorides' De Materia Medica and later on in medieval medical manuscripts and Pharmacopoeias. Actually, it is widely used as herbal medicine for the relief of mild symptoms of mental stress, to aid sleep and for symptomatic treatment of mild (...)
see on pubmed
Musa acuminata and its bioactive metabolite 5-Hydroxymethylfurfural mitigates quorum sensing (las and rhl) mediated biofilm and virulence production of nosocomial pathogen Pseudomonas aeruginosa in vitro.
J Ethnopharmacol.
2020 Jan 10, 246:112242.
Musa acuminata, a tropical plant belongs to the family Musaceae. The fruit peels of this plant have been well documented for their therapeutic value in Asia and Africa. It has also been previously reported for numerous biological applications such as antimicrobial, antioxidant, itching, psoriasis and anti-diarrheal activities. Moreover, M. acuminata peels have been well known for its anti-healing and antiseptic properties and most commonly used for healing wounds and heat burns in South (...)
see on pubmed
Kan-Lu-Hsiao-Tu-Tan, a traditional Chinese medicine formula, inhibits human neutrophil activation and ameliorates imiquimod-induced psoriasis-like skin inflammation.
J Ethnopharmacol.
2020 Jan 10, 246:112246.
Kan-Lu-Hsiao-Tu-Tan (KLHTT) is a popular traditional Chinese medicine for treating various inflammatory diseases.
see on pubmed
on Atopic Dermatitis
Fewer common melanocytic nevi in atopic vs. non-atopic dermatitis children in a birth cohort study.
Int. J. Dermatol..
2019 Dec , 58, (12):e253-e254.
Sublingual immunotherapy of atopic dermatitis in mite-sensitized patients: a multi-centre, randomized, double-blind, placebo-controlled study.
Artif Cells Nanomed Biotechnol.
2019 Dec , 47, (1):3540-3547.
Allergen-specific immunotherapy is widely used for allergic rhinitis and asthma treatment worldwide. This study explored the efficacy and safety of sublingual immunotherapy (SLIT) with the extracts of ( Drops) on house dust mites (HDM)-induced atopic dermatitis (AD). 239 patients with HDM-induced AD were recruited and exposure to a multi-centre, randomized, double-blind, and placebo-controlled clinical trials for 36 weeks, which were randomly divided into placebo and sublingual Drops (...)
see on pubmed
Double blinded, vehicle controlled, crossover study on the efficacy of a topical endocannabinoid membrane transporter inhibitor in atopic Beagles.
Arch. Dermatol. Res..
2019 Dec , 311, (10):795-800.
The endocannabinoid system is important for skin homeostasis and alterations are linked to inflammatory diseases like atopic dermatitis (AD). Importantly, activation of cannabinoid receptor CB2 decreases pruritus and inflammation in mouse models. Reduction of inactivation of endogenous cannabinoids could, therefore, be a therapeutic option for AD. Dogs spontaneously develop AD, which closely mimics the human disease making them suitable to test new therapies. Our study aimed to test the (...)
see on pubmed
